New drug could overcome resistance to CDK4/6 inhibitors in breast cancer
Brest cancer is the most common cancer in women. Among breast tumors that spread to other organs (develop metastasis), 70% belong to a variant, called luminal, whose cells are sensitive to the female sex hormones estrogen and progesterone. In fact, the tumor forms when these hormones order the cells to divide.
Re: New drug could overcome resistance to CDK4/6 inhibitors in breast cancer
Unfortunately for my wife, this "RANK" idea did not pan out. She was on the regimen of Abemaciclib (a CDK4/6 inhibitor), trastuzumab biosimilar, Fulvestrant, and Denosumab. This regimen work for about 10 months.
Linear Mode
